Free tool
FAERS Monitor: Hyftor
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213478 or its brand name (Hyftor, Sirolimus). Reports on generic versions are filed under their own applications.
Reports
13,673
Serious
11,686
85% of reports
Hospitalization
4,681
Death reported
2,174
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use2,127
- drug ineffective1,149
- product use in unapproved indication792
- pyrexia533
- diarrhoea530
- pneumonia501
- drug interaction450
- acute kidney injury443
- thrombotic microangiopathy386
- transplant rejection384
- cytomegalovirus infection355
- condition aggravated320
- nausea318
- toxicity to various agents316
- infection313
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 41 |
| 2005 | 53 |
| 2006 | 51 |
| 2007 | 232 |
| 2008 | 194 |
| 2009 | 294 |
| 2010 | 152 |
| 2011 | 253 |
| 2012 | 231 |
| 2013 | 204 |
| 2014 | 239 |
| 2015 | 315 |
| 2016 | 425 |
| 2017 | 598 |
| 2018 | 845 |
| 2019 | 990 |
| 2020 | 1,021 |
| 2021 | 1,054 |
| 2022 | 1,230 |
| 2023 | 1,170 |
| 2024 | 1,489 |
| 2025 | 1,583 |
| 2026 | 1,009 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,486 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| transplant rejectionSignal | 384 | 77.4 | 69.9 | 27,497 |
| thrombotic microangiopathySignal | 386 | 63.4 | 57.3 | 22,719 |
| cytomegalovirus infectionSignal | 355 | 33.6 | 30.2 | 10,949 |
| product use in unapproved indicationSignal | 792 | 4.9 | 4.6 | 2,498 |
| acute kidney injurySignal | 443 | 4.5 | 4.1 | 1,192 |
| drug interactionSignal | 450 | 4.4 | 4.0 | 1,173 |
| off label useSignal | 2,127 | 3.7 | 3.6 | 4,448 |
| infectionSignal | 313 | 3.3 | 3.0 | 511 |
| toxicity to various agentsSignal | 316 | 2.9 | 2.6 | 390 |
| pneumoniaSignal | 501 | 2.4 | 2.2 | 406 |
| pyrexiaSignal | 533 | 2.4 | 2.2 | 428 |
| condition aggravated | 320 | 1.6 | 1.5 | 76 |
| drug ineffective | 1,149 | 1.3 | 1.3 | 106 |
| diarrhoea | 530 | 1.3 | 1.2 | 30 |
| nausea | 318 | 0.6 | 0.6 | 78 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.